Oculis Holding AG Ordinary shares (OCS NASDAQ) stock market data APIs
$18.4127
0.07(0.4%)
as of July 10, 2025
Try our APIs with
free plan!
Oculis Holding AG Ordinary shares Financial Data Overview
Price chart is built with
Anychart
Oculis Holding AG, a clinical-stage biopharmaceutical company, develops drug candidates to treat ophthalmic diseases in Switzerland, Iceland, and internationally. The company's lead product candidate is OCS-01, a topical dexamethasone optireach formulation, which is in Phase 3 clinical trials for the treatment of diabetic macular edema; OCS-02, a topical biologic candidate that is in Phase 2b clinical trials for the treatment for dry eye disease; and OCS-05, a disease modifying neuroprotective agent for neurological damage with indications for glaucoma, dry age-related macular degeneration and diabetic retinopathy, and acute optic neuritis. Oculis Holding AG was formerly known as Oculis SA and changed its name to Oculis Holding AG in March 2023. The company was founded in 2017 and is based in Zug, Switzerland.
Prev. Close
18.4127
Open
18.4847
High
18.4847
Low
18.2176
52 wk Range
10.79-23.08
Market Cap
939 M
Shares Outstanding
51 034 K
Revenue
749 K
EPS
-0.69
Beta
0.144
Why to choose EODHD?
Prices start at $19.99
24/7 Live support
Robust, powerful and reliable data
API Simplicity of a few lines of code
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
Get Oculis Holding AG Ordinary shares data using free add-ons & libraries
Get Oculis Holding AG Ordinary shares Fundamental Data
Oculis Holding AG Ordinary shares Fundamental data includes:
- Net Revenue: 749 K
- EBITDA: -77 394 000
- Earnings Per Share:
- Income Statements
- Balance Sheets
- Cash flows
Plans with Fundamental data
Starting from
$
59.99
/mo.
End-of-day & Earnings data
What’s included:
- Latest Release: 2025-05-08
- EPS/Forecast: -0.46
What’s included:
- End of Day, Intraday and Live APIs
- Splits
- Dividends
Oculis Holding AG Ordinary shares News
New
Oculis Reports Q3 2023 Financial Results and Provides Company Update
Reported lead product candidate OCS-01 eye drop met both primary endpoints in Phase 3 OPTIMIZE trial for inflammation and pain after cataract surgery following positive readout of Stage 1 of the Phase...
Oculis to Present at Upcoming November Investor Conferences
ZUG, Switzerland, and BOSTON, Nov. 08, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis”), a global biopharmaceutical company purposefully driven to save sight and improve eye c...
Oculis to Present a Late-Breaking Abstract at the American Academy of Ophthalmology 2023 Annual Meeting on the Positive Stage 1 Results from Phase 3 DIAMOND Trial for Diabetic Macular Edema
ZUG, Switzerland and BOSTON, Nov. 01, 2023 (GLOBE NEWSWIRE) -- Oculis Holding AG (Nasdaq: OCS) (“Oculis” or the “Company”), a global biopharmaceutical company purposefully driven to save sig...
Positive Phase 3 Stage 1 DIAMOND Trial Results of OCS-01 in Diabetic Macular Edema Presented at 23rd EURETINA Congress
OCS-01’s positive results in Stage 1 of the Phase 3 DIAMOND trial for diabetic macular edema (DME) were presented as a late-breaking abstract showing that the trial met primary and secondary endpoin...
Try our APIs
with free plan!
Or get access to advanced financial data starting only $19.99
TRY NOW
- Flexibility: No long-term commitments, just a minimum of one month
- Instant access: Get your API key and instructions within seconds of subscribing
- Price stability: Locked-in rates for subscribed users, never changing
All-In-One
$99.99/mo.
What’s included:
- API Calls per Day: 100 000/day
- API Requests per Min.: 1000/minute
- Type of Usage: Personal use
Data access:
Historical EOD, Fundamental, Real-Time, Intraday, Live (Delayed), Technical & Screener APIs, News Feed, 40 000 Stock Logos and many more. See a full list.
